September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Shadi Tabibian: A New Era in von Willebrand Disease Treatment

Shadi Tabibian/LinkedIn

Jun 23, 2026, 15:27

Shadi Tabibian: A New Era in von Willebrand Disease Treatment

Shadi Tabibian, Deputy of research at Blood Diseases Research Centers in Iran University of Medical Sciences, shared a post on LinkedIn:

“A New Era in von Willebrand Disease Treatment

For decades, the management of von Willebrand disease has relied mainly on von Willebrand factor concentrates,desmopressin,antifibrinolytic agents, and hormonal therapies.

Although these treatments remain effective for many patients, important unmet needs persist, including treatment burden, variable clinical response, limited prophylactic options, and reduced quality of life.

A new generation of therapeutic strategies is now emerging.

These approaches include:

Antibodies designed to increase endogenous VWF and factor VIII levels
Novel agents for type 2B VWD-associated thrombocytopenia
FVIII-mimetic and rebalancing therapies
Engineered factor VIII molecules with prolonged half-life
Platelet-inspired synthetic nanoparticles
Long-acting antifibrinolytic strategies using siRNA
Gene therapy, allele-selective silencing, and CRISPR-based gene editing

The most important shift is the movement away from a one-size-fits-all model toward phenotype-directed and personalized treatment.

Not every therapy will be appropriate for every subtype of VWD. Future success will depend on matching the mechanism of treatment to the patient’s VWD type, bleeding phenotype, clinical needs, and individual risk profile.

These innovations may ultimately reduce treatment burden, expand prophylactic options, and improve the quality of life of people living with VWD.”

Shadi Tabibian: A New Era in von Willebrand Disease Treatment